Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5999697

CC(c1ccncc1)c1ccc(Cl)c(Cl)c1.N

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.50
SLC6A2 P23975 6/20 0.50
SLC6A3 Q01959 6/20 0.50
CYP3A4 P08684 5/20 0.50
CYP2D6 P10635 5/20 0.50
CYP19A1 P11511 2/20 0.42
AKT1 P31749 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KCNH2 Q12809 2/20 0.38
NPY5R Q15761 1/20 0.37
PTGS1 P23219 1/20 0.37
AHR P35869 1/20 0.37
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL6000408 0.80 SLC6A4 (0.49) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
SCHEMBL12204112 0.79 IDO1 (0.53) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
SCHEMBL12204722 0.78 CYP19A1 (0.68) CYP3A4CYP19A1AKT1CYP2C19
SCHEMBL29173259 0.78 CYP19A1 (0.48) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
Ammonia Solution, Strong SCHEMBL5999595 0.77 SLC6A4 (0.50) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
Ammonia Solution, Strong SCHEMBL5999637 0.77 CYP19A1 (0.45) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
SCHEMBL724559 0.77 CYP3A4 (0.52) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
Ammonia Solution, Strong SCHEMBL5999691 0.76 PDE1B (0.42) SLC6A4SLC6A2SLC6A3CYP19A1LMNA
SCHEMBL4033388 0.76 SLC6A2 (0.63) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
Ammonia Solution, Strong SCHEMBL5999466 0.74 AKR1C3 (0.42) SLC6A4SLC6A2SLC6A3CYP3A4CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C SLC6A4 1569/4885SLC6A2 1494/4885SLC6A3 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.